Abstract:Background: Immune checkpoint blockade (ICB) therapies have achieved great promising results in clinics. However, a large proportion of the patients do not respond to these therapies. Therefore, it is essential to develop new immunotherapy for colorectal cancer. Recent studies have revealed the important roles of tumor-infiltrating cytotoxic T lymphocytes (CTL) in enhancing the immunosensitivity of cancer cells to ICB. Here, we identified that IFI35 induced highly proliferative and cytotoxic states of CD8+ T cells, as well as boosted anti-tumor immunotherapy efficacy for CRC.Methods: In this study, we characterized that the expression of IFI35 is associated with the activation and cytotoxicity of CD8+ T cells by analyzing the public TCGA and proteomic databases. Then we engineered IFI35 expressing murine colon cancer cells and tested their roles on anti-tumor immunity in both immunodeficient and immunocompetent mouse models. Flow cytometry and immunohistochemistry were applied to assess the immune microenvironment. Western blot analysis was used to identify the potential down-streaming signaling pathway regulated by IFI35. We further investigated the efficacy of the IFI35 in combination with various immunotherapeutic treatments. Findings: The transcriptional and proteomic analysis of the activation and cytotoxicity of CD8+ T cells in human cancer samples demonstrated that IFI35 expression is associated with increased CD8+ T cell infiltration and predicted a good outcome in colorectal cancer. The number and cytotoxicity of CD8+ T cells were significantly increased in IFI35-overexpressing tumors. Mechanistically, we identified that the IFNg-STAT1-IRF7 signal axis stimulated IFI35 expression, and tumor-secreted IFI35 promoted the proliferation and cytotoxicity of CD8+ T cells by activating the PI3K/mTOR/AKT signaling pathway in vitro. Furthermore, IFI35 sensitized colorectal cancer cells to immune therapy.Interpretation: Our results emphasized that IFI35 induced a robust expansion of activated CD8+ T cells in colorectal cancer. And it may be a promising biomarker for predicting prognosis and immunotherapy in CRC. Funding Information: This work was supported by the Key-Area Research and Development Program of Guangdong Province (No.2019B020229002), Science and Technology Planning Project of Guangzhou (No. 201902020009, SL2023A04J01608).Declaration of Interests: Authors declare that they have no competing interests.Ethics Approval Statement: All experiments were approved by the Research Ethical Committee of the Sixth Affiliated Hospital of Sun Yet-sen University and in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory animals.

Association of CD8+TILs co-expressing granzyme A and interferon-γ with colon cancer cells in the tumor microenvironment

Abstract 1179: A single-cell atlas of human gastric malignancy reveals CD8+ T cell rejuvenation as a mediator of immunotherapeutic response

Intratumoral Injection of Interferon Gamma Promotes the Efficacy of Anti-Pd1 Treatment in Colorectal Cancer

Interferon-γ in the tumor microenvironment promotes the expression of B7H4 in colorectal cancer cells, thereby inhibiting cytotoxic T cells

GRANZYME A-PRODUCING CD4 T CELLS ARE DRIVERS OF IMMUNE CHECKPOINT BLOCKADE-INDUCED COLITIS

A Pan-Cancer Analysis of the Granzyme Family Based on the TCGA Database and Single-Cell RNA Sequencing Data.

Clinical significance of CD8 + T cell immunoreceptor with Ig and ITIM domains + in locally advanced gastric cancer treated with SOX regimen after D2 gastrectomy.

Tertiary Lymphoid Structure-Associated B Cells Enhance Response to Programmed Cell Death Protein 1 Blockade in Cancer Immunotherapy

Gasdermin E benefits CD8+T cell mediated anti-immunity through mitochondrial damage to activate cGAS-STING-interferonβ axis in colorectal cancer

Granzymes Expression Patterns Predict Immunotherapy Response and Identify the Heterogeneity of CD8 T Cell Subsets

ILC1-derived IFN-γ regulates macrophage activation in colon cancer

Prognostic role of tumor-infiltrating lymphocytes in gastric cancer: a meta-analysis and experimental validation

G-CSF and G-CSFR Modulate CD4 and CD8 T Cell Responses to Promote Colon Tumor Growth and Are Potential Therapeutic Targets

Interaction Networks Converging on Immunosuppressive Roles of Granzyme B: Special Niches Within the Tumor Microenvironment

Tumor-Secreted IFI35 Promotes Proliferation and Cytotoxic Activity of CD8+ T Cells&nbsp;Through PI3K/Akt/mTOR Signaling Pathway in Colorectal Cancer

CXCL8 Associated Dendritic Cell Activation Marker Expression and Recruitment as Indicators of Favorable Outcomes in Colorectal Cancer

CD8+CXCR5+ T Cells in Tumor-Draining Lymph Nodes Are Highly Activated and Predict Better Prognosis in Colorectal Cancer.

Abstract 2698: TCF-1 is a critical regulator of intraepithelial lymphocytes in colorectal carcinoma

Tertiary Lymphoid Structure-Associated B Cells Enhance CXCL13+CD103+CD8+ Tissue-Resident Memory T-Cell Response to Programmed Cell Death Protein 1 Blockade in Cancer Immunotherapy

Granzyme B+ B Cells Detected by Single-Cell Sequencing Are Associated with Prognosis in Patients with Intrahepatic Cholangiocarcinoma Following Liver Transplantation.

Co-enrichment of CD8-positive T cells and macrophages is associated with clinical benefit of tislelizumab in solid tumors